Practical Applications of S1P Therapeutics for the Treatment of Relapsing Forms of Multiple Sclerosis


Program Dates: March 11th, 2022 - March 10th, 2023
Credits: 1.0 AMA PRA Category 1 Credit™; 1.0 CNE Contact Hour; 1.0 CPE Contact Hour (0.10 CEUs)


Practical Applications of S1P Therapeutics for the Treatment of Relapsing Forms of Multiple Sclerosis

Program Overview

This CME/CE program is derived from content presented at the ACTRIMS Forum 2022. The educational activity, chaired by Fred D. Lublin, MD, will analyze best practices for incorporating sphingosine 1 phosphate (S1P) therapeutics in treatment plans for patients with multiple sclerosis (MS). The expert faculty will first outline the pathophysiology and specific science of all S1P receptor modulators. Following, current trial data regarding the safety and efficacy of S1P receptor modulators will be analyzed, along with the clinical implications for the multiple sclerosis patient. The faculty will conclude with a discussion of engaging the interprofessional team to create individualized treatment plans to improve patient outcomes and adherence to therapy in the multiple sclerosis landscape.

Target Audience

Neurologists and other healthcare professionals involved in the treatment and management of patients with relapsing multiple sclerosis

Agenda

I. Welcome and Introductions – Fred D. Lublin, MD

II. Sphingosine 1 Phosphate Clinical Science Update as a Therapeutic Target for Relapsing Forms of Multiple Sclerosis – Stephanie K. Tankou, MD, PhD

III. Clinical Trial Review of S1P Receptor Modulators for the Treatment of Patients with Relapsing Forms of Multiple Sclerosis – Yinan Zhang, MD

IV. Individualized Treatment Strategies for S1P-Based Therapeutics to Optimize Adherence and Tolerance to Improve Outcomes for Patients with Multiple Sclerosis – Jiwon Oh, MD

Learning Objectives

  1. Understand multiple sclerosis disease pathophysiology and the specific science of all S1P receptor modulators
  2. Review recent clinical trial data for S1P receptor modulator therapeutic options to treat patients with relapsing forms of multiple sclerosis
  3. Implement individualized treatment strategies that balance safety with efficacy to optimize S1P receptor therapeutic adherence and improve outcomes for patients with MS

Faculty 

Fred D. Lublin, MD (Course Chair)
Saunders Family Professor of Neurology Director
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, New York

 

Jiwon Oh, MD
Assistant Professor, Division of Neurology
University of Toronto
Toronto, Ontario, Canada

 

Stephanie K. Tankou, MD, PhD
Assistant Professor
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, New York

 

Yinan Zhang, MD
Department of Neurology and Neurotherapeutics
University of Texas Southwestern Medical Center
Dallas, Texas

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Fred D. Lublin, MD Consultant/Advisor: Acorda Therapeutics; Actelion Pharmaceuticals US, Inc.; Apitope; Atara Biotherapeutics; Avotres Inc.; Banner Life Sciences; Biogen; Brainstorm Cell Therapeutics; Bristol-Myers Squibb; Celgene Corporation; EMD Serono Inc.; Entelexo Biotherapeutics; Genentech, Inc.; GW Pharmaceuticals; Horizon Therapeutics plc; Immunic Therapeutics; Janssen Global Services, LLC; Jazz Pharmaceuticals; Labcorp; Mapi-Pharma Ltd.; MedDay Pharmaceuticals; Medimmune, LLC; Mylan; Neuralight; Neurogene; Novartis AG; Orion Biotechnology; Receptos; Roche; Sanofi Genzyme; SetPoint Medical; Teva Pharmaceuticals; TG Therapeutics, Inc.; Viela Bio, Inc.

Grant/Research Support: Actelion Pharmaceuticals US, Inc.; Biogen; Brainstorm Cell Therapeutics; Novartis AG; Sanofi Genzyme

Stock Options: Avotres Inc.; Neuralight

Speaker’s Bureau: Sanofi Genzyme

Jiwon Oh, MD, PhD Consultant/Advisor: Alexion Pharmaceuticals; Biogen; Bristol-Myers Squibb; EMD Serono Inc.; Novartis AG; Roche

Grant/Research Support: Biogen; EMD Serono Inc.; Roche

Stephanie Tankou, MD, PhD Nothing to disclose
Yinan Zhang, MD Nothing to disclose

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Joseph Feick, PharmD; Gabriell Fiorelli, CRNP and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour.

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEUs) of continuing pharmacy education credit (JA4008190-0000-22-005-H04-P).

Clinicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Bristol-Myers Squibb Company.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol-Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].

BUTTON

Provided by: AcademicCME-web